Montelukast, an Anti-asthmatic Drug, Inhibits Zika Virus Infection by Disrupting Viral Integrity

Chen, Yongkang; Li, Yuan; Wang, Xiaohuan; Zou, Peng

doi:10.3389/fmicb.2019.03079

Cited by 31 publications

(40 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A widely used drug among patients with asthma is montelukast, which have bronchodilator and anti-inflammatory effects, it even decreases the need for high doses of steroids ( 23 ). Moreover, montelukast has exhibited antiviral efficacy against ZIKA infection in vitro and in vivo, showing that montelukast could disrupt the integrity of the virions to release the viral genomic RNA, hence irreversibly inhibiting viral infectivity ( 24 ).…”

Section: Discussionmentioning

confidence: 99%

Increased Risk of Hospitalization and Death in Patients with COVID-19 and Pre-existing Noncommunicable Diseases and Modifiable Risk Factors in Mexico

Hernández-Galdamez

González-Block

Romo-Dueñas³

et al. 2020

Archives of Medical Research

127

113

View full text Add to dashboard Cite

Background The population in Mexico has high prevalence rates of noncommunicable diseases (NCDs). Hospitalization and death of COVID-19 patients in the countries most affected by the pandemic has been associated to chronic comorbidities. Objective To describe the prevalence of NCDs in patients with COVID-19 in Mexico and analyze the increased risk due to comorbidities and risk factors on hospitalization, utilization of intensive care units and death. Methods A cross-sectional study was performed from 212,802 confirmed COVID-19 cases reported by the Ministry of Health up to June 27, 2020. Odds ratios were performed using logistic regression model. Results Up to 47.40% of patients with COVID-19 diagnosis were also reported with a comorbidity, with hypertension being the most frequent (20.12%). The report of at least one NCD significantly increased the risk of death with respect to patients without such diagnoses. Chronic kidney disease increased the risk of death the most (OR 2.31), followed by diabetes (OR 1.69), immunosuppression (OR 1.62), obesity (OR 1.42), hypertension (OR 1.24), chronic obstructive pulmonary disease (OR 1.20). The comorbidities that most increased the risk of ICU and of intubation were diabetes, immunosuppression and obesity. Conclusion NCD comorbidities increase the severity of COVID-19 infection. Given high NCD prevalence rates among the Mexican population, the pandemic poses a special threat to the health system and to society. Special prevention measures need to be strengthened for persons with NCD diagnoses in the short-term. In the mid-term, disease control strategies need to be improved to protect these patients against COVID-19 severity.

show abstract

Section: Discussionmentioning

confidence: 99%

Increased Risk of Hospitalization and Death in Patients with COVID-19 and Pre-existing Noncommunicable Diseases and Modifiable Risk Factors in Mexico

Hernández-Galdamez

González-Block

Romo-Dueñas³

et al. 2020

Archives of Medical Research

127

113

View full text Add to dashboard Cite

show abstract

“…TNF-α, IL-6 and IL-1β levels (66,67). A previous study suggests that it inhibits Zika virus by disrupting the integrity of the virions (68). It has been predicted by other groups as well to bind to main protease of SARS-CoV2 (69).…”

Section: Molecules Docking To Sars-cov2 Enzymesmentioning

confidence: 93%

Identification of drugs targeting multiple viral and human proteins using computational analysis for repurposing against COVID-19

Kumar

Kumari

Agnihotri

et al. 2020

Preprint

View full text Add to dashboard Cite

The SARS-CoV2 is a highly contagious pathogen that causes COVID-19 disease. It has affected millions of people globally with an average lethality of ~3%. Unfortunately, there is no standard cure for the disease, although some drugs are under clinical trial. Thus, there is an urgent need of drugs for the treatment of COVID-19. In the current studies, we have used state of the art bioinformatics techniques to screen the FDA approved drugs against nine SARS-CoV2 proteins to identify drugs for quick repurposing. The strategy was to identify potential drugs that can target multiple viral proteins simultaneously. Additionally, we analyzed if the identified molecules can also affect the human proteins whose expression is differentially modulated during SARS-CoV2 infection. The differentially expressed genes (DEGs) as a result of SARS-CoV2 infection were identified using NCBI-GEO data (GEO-ID: GSE-147507). Targeting such genes may also be a beneficial strategy to curb disease manifestation. We have identified 74 molecules that can bind to various SARS-CoV2 and human host proteins. Their possible use in COVID-19 have also been reviewed in detail. We hope that this study will help development of multipotent drugs, simultaneously targeting the viral and host proteins, for the treatment of COVID-19.

show abstract

“…For Influenzae A virus, an inhibition of the expression of the viral genome was observed with MK (Landeras-Bueno et al, 2016). For flaviviridae, in particular Zika virus, an irreversible and early inactivation of the virus was reported, probably due to some damage to the lipid membrane (Chen et al, 2020). Three distinct mechanisms were proposed to support the beneficial impact of MK on Zika virus: i) a direct antiviral action, ii) an antagonization of the cytokine storm, and iii) an inhibition of the vertical transmission by a MK-related neuroprotective effect on the brain of fetus.…”

Section: Properties Of Mk Related To Sars-cov-2 Antiviral Propertiesmentioning

confidence: 99%

Montelukast Drug May Improve COVID-19 Prognosis: A Review of Evidence

Barre¹,

Sabatier

Annweiler

2020

Front. Pharmacol.

View full text Add to dashboard Cite

With the lack of effective therapy, chemoprevention and vaccination, focusing on the immediate repurposing of existing drugs gives hope of curbing the pandemic. Interestingly, montelukast, a drug usually used in asthma, may be proposed as a potential adjuvant therapy in COVID-19. The aim of the present article was to review the properties of montelukast that could be beneficial in COVID-19. Ten experimentally supported properties were retrieved, either related to SARS-CoV-2 (antiviral properties, prevention of endotheliitis and of neurological disorders linked to SARS-CoV-2), and/or related to the host (improvement of atherogenic vascular inflammation, limitation of the ischemia/reperfusion phenomenon, improvement of respiratory symptoms), and/or related to serious COVID-19 outcomes (limitation of the cytokine storm, mitigation of acute respiratory distress syndrome), and/or related to tissue sequelae (antioxidant properties, anti-fibrosis effects). Based on gathered theoretical evidence, we argue that montelukast should be further tested to prevent and treat COVID-19 outcomes.

show abstract

Montelukast, an Anti-asthmatic Drug, Inhibits Zika Virus Infection by Disrupting Viral Integrity

Cited by 31 publications

References 56 publications

Increased Risk of Hospitalization and Death in Patients with COVID-19 and Pre-existing Noncommunicable Diseases and Modifiable Risk Factors in Mexico

Increased Risk of Hospitalization and Death in Patients with COVID-19 and Pre-existing Noncommunicable Diseases and Modifiable Risk Factors in Mexico

Identification of drugs targeting multiple viral and human proteins using computational analysis for repurposing against COVID-19

Montelukast Drug May Improve COVID-19 Prognosis: A Review of Evidence

Contact Info

Product

Resources

About